Onda Masanori
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Methods Mol Biol. 2012;907:627-43. doi: 10.1007/978-1-61779-974-7_35.
Recombinant immunotoxin (RIT) contains the Fv portion of the antibody fused to the truncated form of toxin and are ongoing in clinical trials for cancer therapy. To obtain high yields of products, RITs are produced in Escherichia coli (E. coli). As the endotoxin came from E. coli cells and is harmful to animals, it is important to produce the RITs with low endotoxin. This section describes the protocols to produce RITs containing low level of endotoxins.
重组免疫毒素（RIT）包含与截短形式的毒素融合的抗体Fv部分，目前正处于癌症治疗的临床试验阶段。为了获得高产率的产品，RIT在大肠杆菌（E. coli）中生产。由于内毒素来自大肠杆菌细胞且对动物有害，因此生产低内毒素的RIT非常重要。本节介绍生产低内毒素水平RIT的方案。
